鼻咽癌组织ERCC1的表达及其临床意义

Expression of ERCC1 in nasopharyngeal carcinoma and its chinical significance

目的:探讨核苷酸切除修复交叉互补基因(ERCC1)在鼻咽癌(NPC)组织中表达及其与顺铂(DDP)化疗疗效的关系。方法:82例经鼻咽部肿物活检确诊为鼻咽低分化鳞癌患者接受DDP为基础化疗,应用免疫组化法检测鼻咽部癌组织ERCC1基因蛋白表达,并设34例NPC癌旁上皮组织为对照组。结果:在NPC癌旁上皮组织中ERCC1的阳性率为88.2%,明显高于NPC组织中ER-CC1阳性率(63.4%),P<0.05;ERCC1基因蛋白表达阳性患者化疗有效率为36.5%,ERCC1阴性患者有效率为63.3%,其差异有统计学意义,P<0.05。ERCC1表达与NPC患者年龄有关(P<0.05),与性别、T分期、N分期及M分期无关,P>0.05。结论:ERCC1异常表达是NPC DDP化疗耐药的一个重要因素,检测ERCC1基因有助于预测NPC患者对顺铂化疗敏感性。

OBJECTIVE：To explore the relationship between ERCC1 protein expression and the treatment of cisplatin-based chemotherapy in nasopharyngeal carcinoma（NPC）.METHODS：The biopsy specimens obtained through nasopharyngeal endoscopy from 82 cases of NPC and 34 cases of normal nasopharyngeal tissues adjacent to the cancer were collected at diagnosis.Immunohisto-chemical assay was conducted with monoclonal antiboby in these specimens to evaluate the expression of ERCC1 gene.RESULTS：The positive expression rate of ERCC1 protein in NPC（63.4%） was significantly lower than that in the normal nasopharyngeal tissues adjacent to the cancer（88.2%,P〈0.05）.The response rates of cisplatin-based chemotherapy in the negative group and positive expression group of ERCC1 were 63.3% and 36.5% respectively,being a significant difference（P〈0.05）.There was a significant correlation between the expression of ERCC1 with the age（P〈0.05）,but no significant correlation in the gender,T staging,N staging and M staging of NPC patients（P〉0.05）.CONCLUSIONS：The abnormal expression of ERCC1 is a molecule marker of chemotherapy sensitivity in NPC patients treated with cisplatin-based chemotherapy.This study may provide a new sight for tailor chemotherapy to individual NPC patients.